| Form | Liquid |
|---|
| Host Species | Human |
|---|
| Clonality | Monoclonal |
|---|
| Isotype | IgG1, kappa |
|---|
| Purity | >95% purity as determined by SDS-PAGE. |
|---|
| Purification | Protein A/G purified from cell culture supernatant. |
|---|
| Concentration | 1.14mg/ml |
|---|
| Endotoxin Level | Please contact the lab for this information. |
|---|
| Applications | ELISA, Bioactivity: FACS, Functional assay, Research in vivo |
|---|
| Species Reactivity | Human cytomegalovirus (HCMV/HHV-5) |
|---|
| Target | Envelope glycoprotein B, gB, UL55 |
|---|
| Storage Buffer | 0.01M PBS, pH 7.4. |
|---|
| Stability and Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
|---|
| Expression System | Mammalian Cells |
|---|
| Accession Number | P06473 |
|---|
| Background | Fiztasovimab (NPC-21; EV2038) is a fully human IgG1λ mAb against human cytomegalovirus (hCMV). Fiztasovimab acts neutralizing activity by binding to the antigenic domain 1 of glycoprotein B on hCMV envelope. Fiztasovimab inhibits cell-to-cell transmission of hCMV.
|
|---|
| Alternative Names | C23, MCAC23, TI-23, 153101-26-9 |
|---|
| Note | For research use only. Not suitable for clinical or therapeutic use. |
|---|